InspireMD (NYSE:NSPR) Now Covered by StockNews.com

Analysts at StockNews.com initiated coverage on shares of InspireMD (NYSE:NSPR) in a research note issued to investors on Sunday. The firm set a “sell” rating on the stock.

Separately, Lake Street Capital started coverage on InspireMD in a research report on Wednesday, December 11th. They set a “buy” rating and a $5.00 price objective on the stock.

InspireMD Stock Down 4.2 %

Shares of NYSE NSPR opened at $3.22 on Friday. The firm has a market capitalization of $83.99 million, a P/E ratio of -4.29 and a beta of 1.00. The stock’s 50-day simple moving average is $2.83 and its two-hundred day simple moving average is $2.76. InspireMD has a twelve month low of $1.81 and a twelve month high of $3.80.

Hedge Funds Weigh In On InspireMD

Institutional investors have recently modified their holdings of the company. Parkman Healthcare Partners LLC boosted its holdings in InspireMD by 721.2% during the 4th quarter. Parkman Healthcare Partners LLC now owns 854,716 shares of the company’s stock valued at $2,248,000 after acquiring an additional 750,635 shares during the period. Essex Investment Management Co. LLC purchased a new stake in InspireMD during the 4th quarter valued at about $191,000. Northern Trust Corp boosted its holdings in InspireMD by 103.7% during the 4th quarter. Northern Trust Corp now owns 48,022 shares of the company’s stock valued at $126,000 after acquiring an additional 24,452 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in InspireMD by 153.2% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 30,133 shares of the company’s stock valued at $79,000 after acquiring an additional 18,233 shares during the period. Finally, Legato Capital Management LLC purchased a new stake in InspireMD during the 4th quarter valued at about $47,000. 44.78% of the stock is currently owned by institutional investors.

InspireMD Company Profile

InspireMD, Inc, a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem lesions.